{
    "clinical_study": {
        "@rank": "158012", 
        "acronym": "HEPAVALV", 
        "arm_group": [
            {
                "arm_group_label": "Heparin", 
                "arm_group_type": "Experimental", 
                "description": "injection of unfractionated heparin (50 IU / kg)"
            }, 
            {
                "arm_group_label": "NaCl", 
                "arm_group_type": "Placebo Comparator", 
                "description": "without heparin"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess if the non use of heparin sodium during balloon aortic valvuloplasty reduces\n      serious complications due to the procedure, by decreasing the rate of vascular and\n      hemorrhagic complications without increasing the rate of ischeamic events."
        }, 
        "brief_title": "Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Aortic Stenosis, Non-rheumatic", 
        "condition_browse": {
            "mesh_term": [
                "Aortic Valve Stenosis", 
                "Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  be over 18\n\n          -  carry a tight and symptomatic aortic stenosis\n\n          -  have an indication for a ballon aortic valvuloplasty\n\n          -  Subject have signed his written informed consent\n\n        Exclusion Criteria:\n\n          -  Have an absence of femoral surgical approach\n\n          -  have a criticial hemodynamic state, considered as outdrove for the treatment\n\n          -  have a severe aortic failure\n\n          -  allergia to heparin\n\n          -  contraindication to heparin or/and local anaesthetic\n\n          -  be treted by low molecular weight heparin in less than 12 hoursbefore the\n             intervention or by standard heparin in less than 4 hours before the valvulopasty\n\n          -  have a tight but not symptomatic aortic stenosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01823393", 
            "org_study_id": "9026"
        }, 
        "intervention": [
            {
                "arm_group_label": "Heparin", 
                "description": "Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure", 
                "intervention_name": "Heparin", 
                "intervention_type": "Drug", 
                "other_name": "Unfractioned heparin"
            }, 
            {
                "arm_group_label": "NaCl", 
                "description": "valvuloplasty is performed without heparin (placebo injection)", 
                "intervention_name": "NaCl", 
                "intervention_type": "Drug", 
                "other_name": "placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium heparin", 
                "Heparin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "balloon aortic valvuloplasty indication", 
            "heparin", 
            "hemorrhagic", 
            "ischemic"
        ], 
        "lastchanged_date": "March 29, 2013", 
        "location": {
            "contact": {
                "email": "c-chauveton@chu-montpellier.fr", 
                "last_name": "claire chauveton", 
                "phone": "0467330924"
            }, 
            "facility": {
                "address": {
                    "city": "Montpellier", 
                    "country": "France", 
                    "zip": "34295"
                }, 
                "name": "Montpellier University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Florence Leclercq, Professor", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Delphine Delseny, Interne", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jean Christophe Macia, PU PH", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Richard Gervasoni, PH", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure", 
        "overall_official": {
            "affiliation": "UH Montpellier", 
            "last_name": "Florence Leclercq, PU PH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of serious complication : vascular, hemorrhagic or ischaemic complication", 
            "safety_issue": "No", 
            "time_frame": "Up to10 days after the valvuloplasty (D1-D10 after the intervention)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01823393"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Non serious complication is complication directly associated with the valvuloplasty which could be vascular complications medically treated (compression), BARC 2 hemorrhage, general procedure complications", 
                "measure": "Number of any non serious complication directly associated with the procedure (vascular, hemorrhagic or ischaemic complication)", 
                "safety_issue": "No", 
                "time_frame": "up to30 days after the valvuloplasty (until D30 after intervention)"
            }, 
            {
                "measure": "number of a serious complication : vascular, hemorrhagic or ischaemic complication", 
                "safety_issue": "No", 
                "time_frame": "up to 30 days after valvuloplasty"
            }
        ], 
        "source": "University Hospital, Montpellier", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Montpellier", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}